Genetic influence on late onset Alzeimer's disease;Influência genética sobre a doença de Alzheimer de início tardio

Revista de Psiquiatria Clinica

Volumn 36, Issue 1, 2009, Pages 16-24

  Barrosl, Alessandra Chiele ^a   Lucatelli, Juliana Faggion ^a   Maluf, Sharbel Weidner ^b   De Andrade, Fabiana Michelsen ^a  

^a UNIVERSIDADE FEEVALE   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Association studies; Late onset Alzheimer's disease; Polymorphisms

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN C1; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE; DIPEPTIDYL CARBOXYPEPTIDASE; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SIGMA OPIATE RECEPTOR;

AGED; ALZHEIMER DISEASE; BRAZIL; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; LATE ONSET ALZHEIMER DISEASE; REVIEW;

EID: 66249148460     PISSN: 01016083     EISSN: 1806938X     Source Type: Journal    
DOI: 10.1590/s0101-60832009000100003     Document Type: Review

References (94)

1. Smith M de AC. DoenÇa de Alzheimer. Rev Br Psiq. 1999;21(s.2):3-7.
2. OrganizaÇão Mundial da SaÚde. Alzheimer's disease. In: Mental health, related diseases. [acessado em 16 mar 2007a]. DisponÍvel em: http://www.afro.who.int/mentalhealth/related-diseases/ alzheimer-disease.html
3. OrganizaÇão Mundial da SaÚde. Alzheimer's disease. In: Al- zheimer's disease: The Brain Killer. [acessado em 16 mar 2007b]. DisponÍvel em: http://www.afro.who.int/en/Section1174/Section1199/ Section1567-6740.html
4. Farrer LA, Myers RH, Cupples LA, St George-Hyslop PH, Bird TD, Rossor MN et al. Transmission and age-at-onset patterns in familial Azheimer's disease: evidence for heterogeneity. Neurology. 1990; 40: 395-403.
5. Cacabelos R. Diagnosis of Alzheimer's disease: defining genetic profiles (genotype vs phenotype). Acta Neurol Scand. 1996; 165: 72-84.
6. Fridman C, GregÓrio CP, Neto ED, Ojopi EPB. AlteraÇõ es genÉticas na doenÇa de Alzheimer. Rev Psiq Clin. 2004; 31: 19-25.
7. Mckhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRA Work Group under the auspices of Departments of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984; 34: 939-44.
8. Folstein MF, Folstein SE, Mchugh PR. Mini-mental state: a practical method for grading the cognitive of patients for the clinician. J Psych Res 1975; 12: 189-98.
9. Strachan T, Read AP. Human molecular genetics. 3.ed. New York: Garland Science, 2004.
10. Mahley RW, Rall S Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genom Hum Genet. 2000; 1: 507-37.
11. Rall S Jr, Weisgraber KH, Mahley RW. Human apolipoprotein E: the complete amino acid sequence. J Biol Chem. 1982; 257: 4171-8.
12. Weisgraber KH, Rall S Jr, Mahley RW. Human E apoprotein heterogene- ity: cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem. 1981; 256: 9077-83.
13. Laws SM, Hone E, Gandy S, Martins RN. Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem. 2003; 84: 1215-36.
14. Bertram L, Mcqueen MB, Mullin K, Blacker D, Tanzi R. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007; 39: 17-23.
15. de Andrade FM, Larrandaburu M, Callegari-Jacques SM, Gastaldo G, Hutz MH. Association of apolipoprotein E polymorphism with plasma lipids and Alzheimer's disease in a Southern Brazilian population. Br J Med Biol Res. 2000; 33: 529-37.
16. Rubinsztein DC. Apolipoprotein E: a review of its roles in lipoprotein metabolism, neuronal growth and repair and as a risk factor for Al- zheimer's disease. Psychol Med. 1995; 2: 223-9.
17. Strittmater WJ, Roses AD. Apolipoprotein E and Alzheimer's disease. Annu Ver Neurosci. 1996; 19: 53-77.
18. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type "4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993; 261: 921-3.
19. Kamboh MI. Molecular genetics of late-onset Alzheimer's disease. Ann Hum Genet. 2004; 68: 381-404.
20. Windler E, Chao Y, Havel RJ. Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. Opposing effects of homolo- gous apolipoprotein E and individual C apolipoproteins. J Biol Chem. 1980; 255: 8303-7.
21. Ki CS, Na DL, Kim DK, Kim HJ, Kim JW. Genetic association of an apoli- poprotein C-I (APOC1) gene polymorphism with late-onset Alzheimer's disease. Neurosci Letters. 2002; 319: 75-8.
22. Petit-Turcotte C, Stohl SM, Beffert U, Cohn JS, Aumont N, Tremblay M et al. Apolipoprotein C-I expression in the brain in Alzheimer's disease. Neurobiol Dis. 2001; 8: 953-63.
23. Poduslo SE, Neal M, Schwankhaus J. A closely linked gene to apo- lipotrotein E may serve as an additional risk factor for Alzheimer's disease. Neurosci Letters. 1995; 201: 81-3.
24. Shi J, Zhang S, Ma C, Liu X, Li T, Tang M, et al. Association between apolipoprotein CI HpaI polymorphism and sporadic Alzheimer's disease in Chinese. Acta Neurol Scand. 2004; 109: 140-5.
25. Xu Y, Berglund L, Ramakrishnan R, Mayeux R, Ngai C, Holleran S, et al. A common Hpa I RFLP of apolipoprotein C-I increases gene transcription and exhibits an ethnically distinct pattern of linkage diserquilibrium with the alleles of apolipoprotein E. J Lipid Res. 1999; 40: 50-8.
26. Retz W, Thome J, Durany N, HarsÀnyi A, Retz Junginger P, Komhuber J, et al. Potencial genetic markers of sporadic Alzheimer's dementia. Psych Genet. 2001; 11: 115-22.
27. Tycko B, Lee JH, Cciappa A, Saxena A, Li CM, Feng L, et al. APOE and APOC1 Promoter polymorphisms and the risk of Alzheimer disease in African American and Caribbean Hispanic individuals. Arch Neurol. 2004; 61: 1434-9.
28. Scacchi R, Gambina G, Ruggeri M, Martini MC, Ferrari G, Silvestri M, et al. Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease. Neurosci Letters. 1999; 259: 33-6.
29. Hull M, Strauss S, Berger M, Volk B, Bauer J. Inflammatory mechanisms in Alzheimer's disease. Eur Arch Psych Clin Neurosci. 1996; 246: 124-8.
30. Rocchi A, Pellegrini S, Siciliano G, Murri L. Causative and susceptibility genes for Alzheimer's disease: a review. Brain Res Bulletin. 2003; 61: 1-24.
31. Wang X, Dekosky ST, Ikonomovic MD, Kamboh MI. Distribution of plasma alpha-1-antichymotrymotrypsin levels in Alzheimer disease patients and controls and their genetic controls. Neurobiol Aging. 2002b; 23: 377-82.
32. Kamboh MI, Sanghera DK, Ferrell RE, Dekosky ST. APOE4-associated Alzheimer's disease risk is modified by alpha-1-antichymotrypsin polymorphism. Nature Genet. 1995; 10: 486-8.
33. Dekosky ST, Aston CE, Kamboh MI. Polygenic determinants of Al- zheimer's disease: modulation of the risk by alpha-1-antichymotrypsin. Ann N Y Acad Sci. 1996; 802: 27-34.
34. Wang X, Dekosky ST, Luedecking-Zimmer E, Ganguli M, Kamboh IM. Genetic variation in alpha(1)-antichymotrypsin and its association with Alzheimer's disease. Hum Genet. 2002a; 110: 356-65.
35. Maurice T. Neuro(active)steroids actions at the neuromodulatory sigma1 (sigma1) receptor: biochemical and physiological evidences, consequences in neuroprotection. Pharmacol Biochem Behav. 2006; 84:581-97.
36. Maruszak A, Safranow K, Gacia M, Gabryelewicz T, Slowik A, Styczyn- ska M et al. Sigma receptor type 1 gene variation in a group of polish patients with Alzheimer's disease and mild cognitive impairment. De- ment Geriat Cogn Disord. 2007; 23: 332-8.
37. Uchida N, Ujike H, Tanaka Y, Sakai A, Yamamoto M, Fujisawa Y, et al. A variant of the sigms receptor type-1 gene is a protective factor for Alzheimer disease. Am J Geriatr Psych. 2005; 13: 1062-6.
38. Mattila KM, Rinne JO, Röyttä M, Laippala P, Pietilä T, Kalimo H, et al. Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E4 allele as risk fac- tors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology. J Med Genet. 2000; 37: 766-70.
39. Alvarez R, Alvarez V, Lahoz CH, MartÍnez C, Peña J, SÁnchez JM, et al. Angiotensin converting enzyme and endothelial nitric oxide synthase DNA polymorphism and late onset Alzheimer's disease. J Neurol Neurosurg Psych. 1999; 67: 733-6.
40. Kerr DS, Bevilaqua LR, Bonini JS, Rossato JI, Köhler CA, Medina JH, et al. Angiotensin II blocks memory consolidation through an AT2 recep- tor-dependent mechanism. Psychopharmacol (Berl). 2005; 179: 529-35.
41. Bonini JS, Bevilaqua LR, Zinn CG, Kerr DS, Medina JH, Izquierdo I, et al. Angiotensin II disrupts inhibitory avoidance memory retrieval. Horm Behav. 2006; 50: 308-13.
42. Kölsch H, Jessen F, Freymann N, Kreys M, Hentschel F, Maier W, et al. ACE I/D polymorphism is a risk factor of Alzheimer's disease but not of vascular dementia. Neurosci Letters. 2005; 377: 37-9.
43. Monastero R, Caldarella R, Mannino M, CefalÙ AB, Lopez G, Noto D, et al. Lack of association between angiotensin converting enzyme polymorphism and sporadic Alzheimer's disease. Neurosci Letters. 2002; 335: 147-9.
44. Bergqvist D, Nilsson IM. Hereditary alpha-2-macroglobulin deficiency. Scand J Haemat. 1979; 23: 433-6.
45. Blacker D, Wilcox MA, Laird NM, Rodes L, Horvath SM, Go RCP, et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nature Genet. 1998; 19: 357-60.
46. Dow DJ, Lindsey N, Cairns NJ, Brayne C, Robinson D, Huppert FA, et al. Alpha-2 macroglobulin polymorphism and Alzheimer disease risk in the UK. (Letter) Nature Genet. 1999; 22: 16-7.
47. Rudrasingham V, Wavrant-de-Vrieze F, Lambert JC, Chakraverty S, Kehoe P, Crook R, et al. Alpha-2 macroglobulin gene and Alzheimer disease. (Letter) Nature Genet. 1999; 22: 17-9.
48. Rogaeva EA, Premkumar S, Grubber J, Serneels L, Scott WK, Kawarai T, et al. An alpha-2-macroglobulin insertion-deletion polymorphism in Alzheimer disease. (Letter) Nature Genet. 1999; 22: 19-21.
49. Saunders AJ, Bertram L, Mullin K, Sampson AJ, Latifzai K, Basu S, et al. Genetic association of Alzheimer's disease with multiple polymorphisms in alpha-2-macroglobulin. Hum Mol Genet. 2003; 12: 2765-76.
50. Zappia M, Manna I, Serra P, Cittadella R, Andreoli V, La Russa A, et al. Increased risk for Alzheimer disease with the interaction of MPO and A2M polymorphisms. Arch Neurol. 2004; 61: 341-4.
51. Bian L, Yang JD, Guo TW, Duan Y, Qin W, Sun Y, et al. Association study of the A2M and LRP1 genes with Alzheimer disease in the Han Chinese. Biol Psych. 2005; 58: 731-7.
52. Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, et al. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell. 1995; 82: 331-40.
53. Narita M, Holtzman DM, Schwartz AL, Bu G. Alpha-2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J Neurochem. 1997; 69: 1904-11.
54. Kang DE, Saitoh T, Chen X, Xia Y, Masliah E, Hansen LA, et al. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology. 1997; 49: 56-61.
55. Lendon CL, Talbot CJ, Craddock NJ, Han SW, Wragg M, Morris JC, et al. Genetic association studies between dementia of the Alzheimer's type and three receptors for apolipoprotein E in a caucasian population. Neurosci Lett. 1997; 222: 187-90.
56. Hollenbach E, Ackermann S, Hyman BT, Rebeck GW. Confirmation of an association between a polymorphism in exon 3 of the low-density lipoprotein receptor-related protein gene and Alzheimer's disease. Neurology. 1998; 50: 1905-7.
57. Baum L, Chen L, Ng HK, Chan YS, Mak YT, Woo J, et al. Low density lipo- protein receptor related protein gene exon 3 polymorphism association with Alzheimer's disease in Chinese. Neurosci Lett. 1998; 247: 33-6.
58. Mcilroy SP, Dynan KB, Vahidassr DJ, Lawson JT, Patterson CC, Passmore P. Common polymorphisms in LRP and A2M do not affect genetic risk for Alzheimer disease in Northern Ireland. Am Med Genet. 2001; 105: 502-6.
59. Pericak-Vance MA, Bass MP, Yamaoka LH, Gaskell PC, Scott WK, Terwedow HA, et al. Complete genomic screen in late-onset familial Alzheimer disease: evidence for a new locus on chromosome 12. JAMA. 1997; 278: 1237-41.
60. Scott WK, Yamaoka LH, Bass MP, Gaskell PC, Conneally PM, Small GW, et al. No genetic association between the LRP receptor and sporadic or late-onset familial Alzheimer disease. Neurogenetics. 1998; 1: 179-83.
61. Hogquist KA, Nett MA, Unanue ER, Chaplin DD. Interleukin 1 is processed and released during apoptosis. Proc Natl Acad Sci. 1991; 88: 8485-9.
62. Rogers J. An IL-1-alpha susceptibility polymorphism in Alzheimer's disease: new fuel for the inflammation hypothesis. (Editorial) Neurology. 2000; 55: 464-5.
63. Du Y, Dodel RC, Eastwood BJ, Bales KR, Gao F, Lohmuller F, et al. Association of an interleukin 1-alpha polymorphism with Alzheimer's disease. Neurology. 2000; 55: 480-4.
64. Grimaldi LME, Casadei VM, Ferri C, Veglia F, Licastro F, Annoni G, et al. Association of early-onset Alzheimer's disease with an interleukin-1-alpha gene polymorphism. Ann Neurol. 2000; 47: 361-5.
65. Nicoll JAR, Mrak RE, Graham DI, Stewart J, Wilcock G, Macgowan S, et al. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol. 2000; 47: 365-8.
66. Murphy GM Jr, Claassen JD, Devoss JJ, Pascoe N, Taylor J, Tinklen- berg JR, et al. Rate of cognitive decline in AD is accelerated by the interleukin-1-alpha -889 1 allele. Neurology. 2001; 56: 1595-7.
67. McGeer PL, McGeer EG. Polymorphisms in inflammatory genes and the risk of Alzheimer disease. Arch Neurol. 2001; 58: 1790-2.
68. Kolsch H, Ptok U, Bagli M, Papassotiropoulos A, Schmitz S, Barkow K, et al. Gene polymorphisms of interleukin-1-alpha influence the course of Alzheimer's disease. (Letter) Ann Neurol. 2001; 49: 818-9.
69. Ki CS, Na DL, Kim DK, Kim HJ, Kim JW. Lack of association of the interleukin-1-alpha gene polymorphism with Alzheimer's disease in a Korean population. (Letter) Ann Neurol. 2002;49:817.
70. Green EK, Harris JM, Lemmon H, Lambert JC, Chartier-Harlin MC, St. Clair D, et al. Are interleukin-1 gene polymorphisms risk factors or disease modifiers in AD? Neurology. 2002; 58: 1566-8.
71. Mattila KM, Rinne JO, Lehtimaki T, Roytta M, Ahonen JP, Hurme M. Association of an interleukin 1B gene polymorphism (-511) with Par- kinson's disease in finnish patients. J Med Genet. 2002; 39: 400-2.
72. La Du BN, Adkins S, Kuo CL, Lipsig D. Studies on human serum paraoxo- nase/arylesterase. Chem Biol Interac. 1995; 87: 25-34.
73. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents ac- cumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991; 286: 152-4.
74. Porat ME, Lunetta LK, Cupples A, Huyck M, Green RC, Baldwin CT, et al. Mirage Study Group. Hum Mol Genet. 2006; 15: 77-85.
75. Scacchi R, Gambina G, Martini MC, Broggio E, Vilardo T, Corbo RM. Different pattern of association of paraoxonase Gln192. Arg polymorphism with sporadic late-onset Alzheimer's disease and coronary artery disease. Neurosci Lett. 2003; 339: 17-20.
76. Janka Z, Juhasz A, Rimanoczy AA, Boda K, Marki-Zay J, Kalman J. Codon 311 (Cys. Ser) polymorphism of paraoxonase-2 gene is associ- ated with apolipoprotein E4 allele in both Alzheimer's and vascular dementias. Mol Psych. 2002; 7: 110-2.
77. Barros AC, et al./Rev Psiq ClÍn. 2009;36(1):16-24
78. Pola R, Gaetani E, Flex A, Gerardino L, Aloi F, Flore R, et al. Lack of association between Alzheimer's disease and Gln-Arg 192 Q/R poly- morphism of the PON-1 gene in an Italian population. Dement Geriatr Cogn Disord. 2003; 15: 88-91.
79. Cellini E, Tedde A, Bagnoli S, Nacmias B, Piacentini S, Bessi V, et al. Association analysis of the paraoxonase-1 gene with Alzheimer's disease. Neurosci Lett. 2006; 408: 199-202.
80. Sodeyama N, Yamada M, Itoh Y, Suematsu N, Matsushita M, Otomo E, et al. No association of paraoxonase gene polymorphism with athero- sclerosis or Alzheimer's disease. Neurology. 1999; 53: 1146-8.
81. Kan R, Wang B, Zhang C, Yang Z, Ji S, Lu Z, et al. Association of the HTR6 polymorphism C267T with late-onset Alzheimer's disease in Chinese. Neurosci Lett. 2004; 372: 27-9.
82. Lesch KP, Balling U, Gross J, Strauss K, Wolozin BL, Murphy DL, et al. Organization of the human serotonin transporter gene. J Neural Transm Gen Sect. 1994; 95: 157-62.
83. Li T, Holmes C, Sham PC, Vallada H, Birkett J, Kirov G, et al. Allelic func- tional variation of serotonin transporter expression is a susceptibility factor for late onset Alzheimer's disease. Neuroreport. 1997; 8: 683-6.
84. Oliveira JR, Zatz M. The study of genetic polymorphisms related to serotonin in Alzheimer's disease: a new perspective in a heterogenic disorder. Braz J Med Biol Res. 1999; 32: 463-7.
85. Hu M, Retz W, Baader M, Pesold B, Adler G, Henn FA, et al. Promoter polymorphism of the 5-HT transporter and Alzheimer's disease. Neu- rosci Lett. 2000; 294:63-5.
86. Kunugi H, Ueki A, Otsuka M, Isse K, Hirasawa H, Kato N, et al. Alzheimer's disease and 5-HTTLPR polymorphism of the serotonin transporter gene: no evidence for an association. Am J Med Genet. 2000; 96: 307-9.
87. Ha TM, Cho DM, Park SW, Joo MJ, Lee BJ, Kong BG, et al. Evaluating associations between 5-HTTLPR polymorphism and Alzheimer's disease for Korean patients. Dement Geriatr Cogn Disord. 2005; 20: 31-4.
88. Tsai SJ, Hong CJ, Liu TY, Cheng CY, Liu HC. Association study for a functional serotonin transporter gene polymorphism and late- onset Alzheimer's disease for Chinese patients. Neuropsychobiology. 2001; 44: 27-30.
89. Nitsch RM, Deng M, Growdon JH, Wurtman RJ. Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. J Biol Chem. 1996; 271: 4188-94.
90. Craig D, Donnelly C, Hart D, Carson R, Passmore P. Analysis of the 5HT-2A T102C receptor polymorphism and psychotic symptoms in Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet. 2007; 144: 126-8.
91. Thome J, Retz W, Baader M, Pesold B, Hu M, Cowen M, et al. Associa- tion analysis of HTR6 and HTR2A polymorphisms in sporadic Alzheimer's disease. J Neural Transm. 2001; 108: 1175-80.
92. Holmes C, Arranz MJ, Powell JF, Collier DA, Lovestone S. 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Hum Mol Genet. 1998; 7: 1507-9.
93. Kan R, Wang B, Zhang C, Yang Z, Ji S, Lu Z, et al. Association of the HTR6 polymorphism C267T with late-onset Alzheimer's disease in Chinese. Neurosci Lett. 2004; 372: 27-9.
94. Tsai SJ, Liu HC, Liu TY, Wang YC, Hong CJ. Association analysis of the 5-HT6 receptor polymorphism C267T in Alzheimer's disease. Neurosci Lett. 1999; 276: 138-9.